25 Apr Blockbuster cancer drug developed by Bay Area biotech at center of drug-pricing ‘march-in’ rights controversy
Ron Leuty
San Francisco Business Times, 4/22/2022 ...
Author: Bayh-Dole Coalition
07 Apr US universities fight potential Biden move on drug patents
Paul Basken
Times Higher Education, 4/7/2022
...
07 Apr $150K Prostate Cancer Drug Draws New Attention to ‘March-In’ Rights
Jennifer Henderson
MedPage Today, 4/6/2022 ...
06 Apr Removing patent rights to lower drug costs is dangerous precedent
Walter G. Copan
Denver Post, 4/6/2022 ...
04 Apr A dubious way to lower drug prices
Richard Parrish
Albany Herald, 4/2/2022 ...
31 Mar Biden’s looming prescription drug pricing dilemma
Caitlin Owens
Axios, 3/31/2022
Also published in Axios Vitals ...
31 Mar Stolen innovation cuts out taxpayers
Stacey Campfield
The Tennessean, 3/31/2022
Also published in Yahoo News, the Knoxville News-Sentinel, and the Commercial Appeal ...
28 Mar There are unintended costs of federal efforts to control drug prices
Lou Berneman
Patriot-News, 3/26/2022 ...
25 Mar ‘March-in’ battles heat up as nonprofits petition HHS on 6 drugs as earlier petition awaits decision
Zachary Brennan
Endpoints News, 3/25/2022 ...
25 Mar HHS Again Urged To Use March-In Rights To Cut Drug Costs
Britain Eakin
Law360, 3/24/2022 ...